Cyrille Yann Nicolas Petit

Provides financial services

Manufactures medical equipment

Manufactures and retails diagnostic imaging & medical equipment

Develops and commercialization molecular imaging technologies

Develops and markets medical devices for healing process

Designs, manufactures and sells noble gas polarizer devices & ancillary instruments

Part of Bracco SpA, Blue Earth Diagnostics, Inc. is a company that specializes in Axumin® (fluciclovine F 18) injection, an FDA-approved PET imaging radiopharmaceutical designed to detect and localize suspected recurrent prostate cancer in men with elevated prostate-specific antigen (PSA) levels following prior treatment such as prostatectomy or radiotherapy. The company is based in Burlington, MA. Axumin targets upregulated amino acid transporters in prostate cancer cells, enabling improved visualization of recurrent disease with limited urinary excretion, which aids lesion delineation near the bladder. The company provides support resources including prescribing information, clinical guidelines, reimbursement assistance, imaging center locators, and educational materials to facilitate access and appropriate use. Safety considerations include potential image interpretation challenges, rare hypersensitivity reactions, radiation exposure risks, and uncommon adverse effects such as injection site pain, erythema, and dysgeusia.

Engages in rental of land and other real estate

Engages in research and development of biotechnology products

Operates as a clinical stage company that develops radiopharmaceuticals and oncology drugs